CYTOKINETICS IN THE NEWS
Here you can find the latest articles about Cytokinetics, along with fact sheets describing the company, our clinical programs and background on our areas of disease focus – ALS, heart failure and SMA.
| Date | Title | |
| August 20, 2020, CNBC Fast Money | Under-the-radar biotech name is up 120% this year | |
| July 14, 2020, Endpoints News | Cytokinetics nabs Chinese partner, up to $450M as CV becomes company focus | |
| July 14, 2020, San Francisco Business Times | Biotech legends help launch parasite-fighting startup with deep Stanford ties | |
| March 5, 2020, ALS News Today | Reldesemtiv Wins EMA Orphan Drug Designation for ALS Treatment | |
| December 19, 2019, ALS News Today | Reldesemtiv Earns FDA’s Orphan Drug Designation for ALS Treatment | |
| December 10, 2019, Healio | COSMIC-HF: Omecamtiv mecarbil may improve diastolic function, pulmonary pressures in HF | |
| December 9, 2019, ALS News Today | Reldesemtiv Effects Maintained When Used on Top of Rilutek or Radicava, New Trial Analysis Shows | |
| November 25, 2019, Forbes | As Boomers Age, We Need New Medical Approaches To Heart Disease | |
| July 19, 2019, BioCentury | A half step forward for heart failure as FDA guidance leaves key question unanswered | |
CYTOKINETICS FACT SHEETS
